Lilly expands Gate Bioscience collaboration for molecular-gate protein degraders

Eli Lilly and Gate Bioscience have expanded their drug-discovery collaboration by adding a new target and an option for a second under Gate's Molecular Gate platform.

The partnership is focused on orally delivered small molecules designed to eliminate difficult-to-drug disease proteins through a differentiated protein-degradation mechanism.

Gate will receive an upfront payment and research funding, with an additional payment if Lilly exercises the option for the second target; financial amounts were not disclosed.

Field	Content
Article Type	Deals
Companies	Eli Lilly and Company; Gate Bioscience
Deal Type	Expanded research collaboration and licence agreement
Platform	Molecular Gate
Programme Scope	One additional target plus an option for a second target
Technology/Modality	Oral small-molecule protein degradation
Target Profile	Difficult-to-drug disease proteins
Financial Terms	Upfront payment; research funding; additional payment if second target option is exercised; amounts not disclosed
What Happened	Lilly and Gate Bioscience expanded their existing collaboration by adding one new target and an option for another.
Why It Matters	The expansion signals continued interest from Lilly in Gate's Molecular Gate technology as an approach to therapeutically eliminate proteins that may be challenging to address with conventional small molecules.
Supporting Context	The companies originally established their collaboration in 2025 and are now broadening its scope.
Strategic Rationale	Lilly gains access to additional discovery opportunities while Gate receives further validation and funding for its protein-targeting platform.
Potential Impact	Successful programmes could create orally available therapies against disease-driving proteins that have historically been difficult to drug.
Key Takeaway	Lilly has expanded its Gate Bioscience collaboration to include at least one additional Molecular Gate target.
What to Watch	Selection of the optional second target, disclosure of therapeutic areas and progression of programmes toward candidate nomination.
Primary Source	Gate Bioscience
Relevant Date	5 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com